NCT02953873View on ClinicalTrials.gov

Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients

PHASE4CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

May 5, 2017

Primary Completion Date

September 10, 2018

Study Completion Date

December 14, 2018

Conditions

Immunosuppression

Interventions

DRUG

Tacrolimus Extended Release Capsule

goal trough 5 - 12ng/mL

DRUG

Mycophenolate mofetil

≥500mg twice a day

DRUG

Prednisone

goal dose 5mg daily

DRUG

Mycophenolate Sodium

≥360mg twice a day

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

Sponsors

Collaborators (1)

Astellas Pharma Inc

All Listed Sponsors

collaborator

Astellas Pharma Inc

INDUSTRY

lead

Medical University of South Carolina

OTHER

NCT02953873 - Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter